Hypothesis: Thanks to a stronger weight loss, CagriSema should lead to a superior reduction of MACE compared to Semaglutide in SELECT (where Semaglutide reduced MACE by 20 %)
If regulatory submissions proceed as expected, the earliest plausible timeline for a market authorisation decision in the UK or Europe would be 2026 or 2027 though this is subject to the pace of regulatory review, the completeness of the submission package, and any additional data requests from the MHRA or EMA
Reprod Biol Endocrinol 23 , 108 (2025)
PRODUCT INFORMATION Packaging: 5 x 10 mL vials in one package Composition: Lecithin, riboflavin, bromelain Method of Administration: Mesotherapy fat lipolysis, Direct Injection Injection depth: Subcutaneous fatty layer Needle size : 30G Usage per point: 1 mL with a point interval of 1 cm (face), 1.5-2 mL with a point interval of 1.5-2 cm Maximum dosage: 50-100 mL per treatment session, depending on the treated area Precautions Avoid injecting the area around the eyes
Other investigators have suggested that a NOS-related pathway may also contribute to improve insulin release